The U.S. Food and Drug Administration (FDA) approved a supplemental application for Keytruda (pembrolizumab) for efficacy on June 16, 2020. This approval, designated BLA 125514 S-71, was submitted by sponsor Merck Sharp Dohme and pertains to the drug's demonstrated efficacy.
Background
Pembrolizumab, marketed as Keytruda, is an established immunotherapy. Supplemental applications are submitted to the FDA to request changes to an already approved drug product, which can include new indications, dosing regimens, manufacturing changes, or, as in this case, new efficacy data supporting an expansion or modification of its approved uses. This specific supplemental approval focused on new efficacy data for pembrolizumab.
What this means
A supplemental approval for efficacy indicates that new clinical data has demonstrated additional benefits or confirmed existing ones for Keytruda (pembrolizumab) in a specific context. While the precise details of the new indication or patient population are not specified in the available data, such approvals typically lead to updates in the drug's official prescribing information. This allows clinicians to consider pembrolizumab for an expanded range of patients or conditions, or to use it under modified guidelines, based on the newly validated efficacy. For patients, it signifies potential new treatment options or improved treatment strategies involving pembrolizumab.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) on June 16, 2020. The details are available on the FDA's Drugs@FDA database, specifically for Biologics License Application (BLA) 125514, accessible via accessdata.fda.gov.